Evaluation of Fosaprepitant's Effect on Drug Metabolism in Sarcoma Patients Receiving Ifosfamide-based Multi-day Chemotherapy Regimen
Study Groups:
If you are found to be eligible to take part in this study, you will receive fosaprepitant
during 21-day chemotherapy cycles. You will be randomly assigned (as in a toss of dice) to
1 of 2 study groups, each with 2 divisions:
- If you are in Group A1, you will receive fosaprepitant on Day 1 of Cycle 1.
- If you are in Group A2, you will receive fosaprepitant on Day 1 of Cycle 2.
- If you are in Group B1, you will receive fosaprepitant on Days 1 and 4 of Cycle 1.
- If you are in Group B2, you will receive fosaprepitant on Days 1 and 4 Cycle 2.
You and the study staff will know to which group and division you are assigned. Each time
you receive the drug, you will receive it by vein over about 20-30 minutes.
You will also receive the ifosfamide-based chemotherapy prescribed by your doctor, as well
as standard drugs for preventing nausea and vomiting (such as ondansetron, lorazepam,
diphenhydramine, and promethazine). You will sign a separate consent form that will
describe these treatments in detail, along with their risks.
You will receive dexamethasone before chemotherapy, every day for 5 days, to help prevent
nausea and vomiting.
Before each chemotherapy cycle, you will be given a study diary. Each day, you will record
any side effects you may . You should bring your study diary to every study visit so the
study staff can review it.
Study Visits:
Before each cycle that you receive fosaprepitant, the following tests and procedures will be
performed:
- You will have a physical exam.
- Your vital signs, weight, and performance status will be recorded.
- You will fill out the same questionnaire you did at screening.
- You will be asked about any other drugs you may be taking. Be sure to tell the study
doctor about all drugs (including vitamins, herbal products, and nutritional
supplements), because some drugs/substances will cause side effects when taken at the
same time as fosaprepitant.
- Blood (about 5 teaspoons) will be drawn for routine tests.
Blood (about 1 teaspoon) will also be drawn 2 times each week during Cycles 1 and 2 for
routine tests.
Pharmacokinetic Testing:
On Days 1 and 4 of Cycles 1 and 2 of chemotherapy, blood samples (about 2 teaspoons each
time) will be drawn for pharmacokinetic (PK) testing, when possible. PK testing measures
the amount of study drug in the body at different time points. The blood will be drawn
before you receive ifosfamide, at the end of the infusion, and 4 more times in the 24 hours
after the infusion.
Length of Study:
You may receive up to 6 cycles of chemotherapy (and up to 5 cycles of fosaprepitant). You
will no longer be able to take the study drug if the disease gets worse or if intolerable
side effects occur.
Your participation on the study will be over once you have completed the end-of-study visit.
End-of-Study Visit:
About 3 weeks after your last dose of fosaprepitant, you will return for an end-of-study
visit. At this visit, the following tests and procedures will be performed:
- You will have a physical exam.
- Your vital signs, weight, and performance status will be recorded.
- You will fill out the same questionnaire you did at screening.
- You will be asked about any other drugs you may be taking.
- Blood (about 5 teaspoons) will be drawn for routine tests.
This is an investigational study. Fosaprepitant is FDA approved and commercially available
in combination with other drugs for the prevention of nausea and vomiting that may be caused
by chemotherapy. It is investigational to study how fosaprepitant may affect the drug
levels of ifosfamide in the blood and how many doses should be given.
Up to 36 patients will take part in this study. All will be enrolled at MD Anderson.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Plasma Areas Under the Concentration Curve (AUC) of Ifosfamide
Effect of Fosaprepitant on Ifosfamide metabolism by pharmacokinetics (PK), Day 1 and Day 4 plasma AUC0-24s (area under curve during 24 hours) of ifosfamide. PK measures (AUC) for ifosfamide calculated for participants that complete 2 cycles of chemotherapy and PK blood collection. PK sampling during first 2 chemotherapy cycles, prior to chemotherapy infusion (baseline) and post-infusion (3 hour from initiation of ifosfamide), and 4 , 6, 8, and 24 hour time points from the initiation of ifosfamide infusion on day 1 and day 4 (last infusion of ifosfamide) in first 2 cycles for all patients.
From Day 1 to Day 4 in two 21-days cycles
No
Saroj Vadhan-Raj, MD
Study Chair
UT MD Anderson Cancer Center
United States: Institutional Review Board
2011-0620
NCT01490060
May 2012
Name | Location |
---|---|
UT MD Anderson Cancer Center | Houston, Texas 77030 |